Home > Signal Pathway > AMQUAR单克隆抗体抑制剂 > AMQUAR 单克隆抗体抑制剂

AMQUAR 单克隆抗体抑制剂


  • Infliximab MA1027

    Infliximab, a chimeric human-murine anti-TNFα monoclonal antibody, is widely used for the treatment of inflammatory bowel disease (IBD).

    More
  • Ipilimumab MA1028

    Ipilimumab (MDX-010), a humanized monoclonal antibody against CTLA-4, causes enhanced T-cell reaction, antitumor response, and significant improvement of the overall survival of patients with metastatic melanoma.

    More
  • Bevacizumab MA1013

    Bevacizumab (Avastin), an antiangiogenic anti-VEGF-R monoclonal antibody specifically binds to all VEGF-A isoforms with high affinity, has a rapid impact on tumor-related brain edema in recurrent GB.

    More
  • Brentuximab vedotin  MA1014

    Brentuximab vedotin (SGN-35), a CD30-directed antibody-drug conjugate composed of an anti-CD30 monoclonal antibody linked to the microtubule-disrupting agent, is approved for treating certain patients with CD30-expressing hematologic malignancies.

    More
  • Canakinumab  MA1015

    Canakinumab, a high-affinity human monoclonal anti IL-1β antibody, neutralizing IL-1β-mediated pathways, is approved for treatment of systemic juvenile idiopathic arthritis (SJIA).

    More
  • Current page5, Total Pages8, Total Record38 First Prev 34567 Next Last Goto